Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9BQR3

UPID:
PRS27_HUMAN

ALTERNATIVE NAMES:
Marapsin; Pancreasin

ALTERNATIVE UPACC:
Q9BQR3

BACKGROUND:
The protein Serine protease 27, with alternative names Marapsin and Pancreasin, is encoded by the gene symbol Q9BQR3. It is a member of the serine protease enzyme family, which plays a critical role in various biological processes, including digestion. The expression of Serine protease 27 in pancreatic tissues indicates its importance in the digestive system.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Serine protease 27 offers a promising avenue for the development of new therapeutic approaches. Given its role in the pancreas, this protein could be pivotal in creating treatments for pancreatic disorders and enhancing our understanding of digestive health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.